Archivio delibere
Seduta del 15/07/2011
Delibera del 15 Luglio, n. 374 [file.pdf]
Autorizzazione allo svolgimento dello studio clinico “TMC435hpc3007”, dal titolo: A phase iii, randomized, double- blind, placebo- controlled study to investigate the efficacy, safety and tolerability of tmc435 vs placebo as part of a treatment regimen including peginterferon alfa 2° and ribavirin in hapatitis c, gonotype in infected subjects who relapsed after previous interferon- based therapy.
Organismo richiedente: Janssen cilag (in nome e per conto di tibotec pharmaceuticals ltd
Autorizzazione allo svolgimento dello studio clinico “TMC435hpc3007”, dal titolo: A phase iii, randomized, double- blind, placebo- controlled study to investigate the efficacy, safety and tolerability of tmc435 vs placebo as part of a treatment regimen including peginterferon alfa 2° and ribavirin in hapatitis c, gonotype in infected subjects who relapsed after previous interferon- based therapy.
Organismo richiedente: Janssen cilag (in nome e per conto di tibotec pharmaceuticals ltd
In pubblicazione dal: 15/07/2011